Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Intervalo de ano de publicação
2.
Eur J Prev Cardiol ; 20(2): 301-9, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22345689

RESUMO

AIM: To evaluate whether a multidisciplinary educational program (EP) in cardiovascular prevention (CVP) for children could improve the Framingham cardiovascular risk (FCR) of their parents after one year. METHODS AND RESULTS: This was a prospective community-based study in Brazil during 2010 that randomized students aged 6 to 10 years old to two different approaches to receiving healthy lifestyle information. The control group received written educational material (EM) for their parents about healthy lifestyle. The intervention group received the same EM for parents, and children were exposed to a weekly EP in CVP with a multidisciplinary health team. At onset and end of the study, we collected data from parents and children (weight, height, arterial blood pressure, and laboratory tests). We studied 197 children and 323 parents. Analyzing the parents' FCR we found that 9.3% of the control group and 6.8% of the intervention group had more than a 10% year risk of cardiovascular heart disease (CHD) over the next 10 years. After the children's EP for the year, the intervention group had a reduction of 91% in the intermediate/high FCR group compared with a 13% reduction in the control group, p = 0.002). In the same way, analyzing the FCR of all parents, there was a reduction of the average risk in the intervention group (3.6% to 2.8% respectively, p < 0.001) compared with the control group (4.4% to 4.4%, p = 0.98). CONCLUSION: An educational program in cardiovascular prevention directed at school-age children can reduce the FCR risk of their parents, especially in the intermediate/high risk categories.


Assuntos
Doenças Cardiovasculares/prevenção & controle , Comportamento Infantil , Comportamentos Relacionados com a Saúde , Educação em Saúde , Conhecimentos, Atitudes e Prática em Saúde , Relações Pais-Filho , Prevenção Primária/métodos , Comportamento de Redução do Risco , Adulto , Análise de Variância , Pressão Arterial , Biomarcadores/sangue , Peso Corporal , Brasil/epidemiologia , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/fisiopatologia , Distribuição de Qui-Quadrado , Criança , Dieta/efeitos adversos , Exercício , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Folhetos , Equipe de Assistência ao Paciente , Estudos Prospectivos , Medição de Risco , Fatores de Risco , Abandono do Hábito de Fumar
3.
Arq Bras Cardiol ; 96(3 Suppl 1): 1-68, 2011.
Artigo em Inglês, Português | MEDLINE | ID: mdl-21655875
4.
Arq. bras. cardiol ; 96(3,supl.1): 1-68, 2011. ilus, tab
Artigo em Português | LILACS | ID: lil-588887
7.
J Thromb Thrombolysis ; 23(1): 65-71, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17186395

RESUMO

PURPOSE: To assess the use of antithrombotic therapy among atrial fibrillation (AF) patients in a Brazilian University Heart Hospital (InCor). METHODS AND RESULTS: In a cross-sectional study we analyzed the charts of all patients treated at InCor in five separate days of 2002 (Phase 1). To assess the impact of admission to a cardiology hospital, a follow-up of the AF patients selected in Phase 1 was carried out after 1 year (Phase 2). The prevalence of AF in the 3,764 assessed charts was 8.0% (301 patients). In Phase 1, antiplatelets were prescribed to 21.2% and anticoagulant therapy (ACT) to 46.5% of AF patients; in Phase 2, to 19.9 and 57.8%, respectively. Thus, 32.2% (Phase 1) and 22.2% (Phase 2) of AF patients were not receiving any antithrombotic drug. Among AF patients with previous ischemic stroke (17.6%), only 49% (Phase 1) and 60.4% (Phase 2) were receiving ACT. As many as 34 and 22.6%, respectively, were not receiving any antithrombotic drug. After follow-up, a new acute embolic event was documented in 5.6% of patients, 17% died. CONCLUSIONS: Anticoagulation is underused in AF patients and neither the fact of being treated by cardiologists in a University Hospital, nor the learning time-window of 1 year seemed to improve the antithrombotic care significantly.


Assuntos
Anticoagulantes/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Institutos de Cardiologia , Embolia/prevenção & controle , Fibrinolíticos/uso terapêutico , Inibidores da Agregação de Plaquetas/uso terapêutico , Padrões de Prática Médica/estatística & dados numéricos , Trombose/prevenção & controle , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Fibrilação Atrial/mortalidade , Brasil/epidemiologia , Estudos Transversais , Feminino , Fidelidade a Diretrizes , Hospitais Universitários/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA